RxDoctor Payments Data

Rayleen Villanueva-Rumpf, MD

Internal Medicine · San Antonio, TXNPI 1235101023

Payments from drug & device makers

$1,455in general payments, 2019–2025

Across 74 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$373
  • Astellas Pharma US Inc$286
  • Sanofi-aventis U.S. LLC$261
  • Johnson & Johnson$159
  • Novo Nordisk$119
  • Boehringer Ingelheim$97
  • plus $161 from 5 others

What the payments were for

  • Food & beverage$1,21383%
  • Education$24217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,455 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$24,702
Medicare patients
75
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin162$257,426
OzempicSemaglutide176$235,504
JanuviaSitagliptin Phosphate154$228,479
MyrbetriqMirabegron173$160,195
TrulicityDulaglutide45$93,242
EliquisApixaban107$86,852
JanumetSitagliptin Phos/Metformin Hcl31$46,732
LinzessLinaclotide50$37,693
MounjaroTirzepatide22$30,978
EntrestoSacubitril/Valsartan25$29,754
FarxigaDapagliflozin Propanediol19$21,575
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$15,783
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$14,284
GemtesaVibegron22$11,226
Omeprazole360$9,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$74$275,210185 claims
Boehringer IngelheimJardiance$97$257,426162 claims
Novo NordiskOzempic$119$235,504176 claims
Astellas Pharma US IncMyrbetriq$286$160,195173 claims
Lilly USA, LLCTrulicity, Mounjaro$373$124,22067 claims
Sanofi-aventis U.S. LLCLantus$261$4,18025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →